Real-World Effectiveness of Guselkumab for Induction of Remission in Crohn’s Disease: A Prospective Multicentre Cohort Study with Propensity Score-Matched Comparison to Risankizumab
Authors:
Open Access
- 19 June 2026
- journal article
- Published by Oxford University Press (OUP) in Crohn’s & Colitis 360
- Vol. 8 (2)
Abstract
Background: No head-to-head trials compare selective interleukin-23 inhibitors in Crohn’s disease (CD), leaving clinicians without direct evidence to guide treatment selection. We aimed to evaluate real-world induction effectiveness of guselkumab in CD and perform propensity score-matched (PSM) comparisons against risankizumab. Methods: This prospective multicentre study included adults with moderate-to-severe CD initiating guselkumab in the United Arab Emirates. The primary outcome was clinical remission at Week 12 (Harvey-Bradshaw Index 0.9) and clinical response (86% vs 87%, p = 0.87) between guselkumab and risankizumab, with no significant between-group biomarker differences. Conclusions: Guselkumab demonstrated robust real-world induction effectiveness comparable to risankizumab across clinical and biochemical outcomes. These findings warrant confirmation in larger, longer-term comparative studies with endoscopic endpoints.Keywords
This publication has 24 references indexed in Scilit:
- Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialThe Lancet, 2022
- Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic InterventionJournal of Crohn's and Colitis, 2022
- Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 StudyGastroenterology, 2022
- A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study IIAlimentary Pharmacology & Therapeutics, 2021
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative ColitisNew England Journal of Medicine, 2019
- IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targetingNature Reviews Gastroenterology & Hepatology, 2018
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Using full matching to estimate causal effects in nonexperimental studies: Examining the relationship between adolescent marijuana use and adult outcomes.Developmental Psychology, 2008
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesBMJ, 2007
- A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease GeneScience, 2006